OncoMatch/Clinical Trials/NCT06437574
Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
Is NCT06437574 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Vytorin and Ezetimibe for prostate cancer.
Treatment: Vytorin · Ezetimibe — To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate cancer patients who are in active surveillance and undergoing a planned surveillance biopsy in 3-6 months. Eligible patients will initiate iCL with Vytorin®(group 1, 2, and 3), an FDA-approved combination of ezetimibe and simvastatin used to lower atherogenic low density lipoprotein cholesterol (LDL-C) or Ezetimibe (group 4). Starting dose will be determined by current statin use and LDL-C levels. Dose modifications of VYTORIN will be employed with the goal of achieving LDL-C \<70 mg/dl. Dose adjustment is not allowed for ezetimibe.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Grade: gleason score 3+3gleason score 3+4gleason score 4+3 (gleason)
Prior therapy
Cannot have received: radiotherapy
Cannot have received: chemotherapy
Cannot have received: hormonal therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cedars-Sinai Medical Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify